ECSP003859A - Composicion para el tratamiento de tejidos dañados - Google Patents

Composicion para el tratamiento de tejidos dañados

Info

Publication number
ECSP003859A
ECSP003859A EC2000003859A ECSP003859A ECSP003859A EC SP003859 A ECSP003859 A EC SP003859A EC 2000003859 A EC2000003859 A EC 2000003859A EC SP003859 A ECSP003859 A EC SP003859A EC SP003859 A ECSP003859 A EC SP003859A
Authority
EC
Ecuador
Prior art keywords
treatment
composition
damaged
wound
agent
Prior art date
Application number
EC2000003859A
Other languages
English (en)
Inventor
Paul Vincent Fish
Kevin Neil Dack
Michael John Davies
Jonathan Paul Huggins
Fraser Stuart Mcintosh
Nicholas Laurence Occleston
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP003859A publication Critical patent/ECSP003859A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Agente farmacéutico para uso en el tratamiento (por ejemplo, curación) de tejidos danados, tal como una herida, comprendiendo el agente farmacéutico una composición que comprende: (a) un factor de crecimiento;(b) un agente inhibidor;y, opcionalmente, (c) un vehículo, diluyente o excipiente farmaceúticamente aceptable;pudiendo el agente inhibidor inhibir la acción de al menos una proteína adversa específica (por ejemplo, una proteasa específica) que está regulada positivamente en un entorno de tejido danado, tal como una herida.
EC2000003859A 1999-12-29 2000-12-28 Composicion para el tratamiento de tejidos dañados ECSP003859A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930768.8A GB9930768D0 (en) 1999-12-29 1999-12-29 Composition

Publications (1)

Publication Number Publication Date
ECSP003859A true ECSP003859A (es) 2002-09-27

Family

ID=10867127

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003859A ECSP003859A (es) 1999-12-29 2000-12-28 Composicion para el tratamiento de tejidos dañados

Country Status (12)

Country Link
EP (1) EP1242120A2 (es)
JP (1) JP2003519193A (es)
AR (1) AR027122A1 (es)
AU (1) AU1878201A (es)
CA (1) CA2395487A1 (es)
CO (1) CO5271671A1 (es)
EC (1) ECSP003859A (es)
GB (1) GB9930768D0 (es)
GT (1) GT200000224A (es)
PE (1) PE20011095A1 (es)
UY (1) UY26514A1 (es)
WO (1) WO2001049309A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE60133301T2 (de) 2000-10-16 2009-05-14 Genentech, Inc., South San Francisco Behandlungsverfahren mit wisp-polypeptiden
ATE328606T1 (de) 2001-07-27 2006-06-15 Orthologic Corp Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera
WO2003029819A1 (en) * 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Method of screening preventive/remedy for bone/joint diseases
AU2003256343B2 (en) 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives
EP1559431B1 (en) 2003-12-31 2007-03-28 Orthologic Corp. Pharmaceutical composition for thrombin peptide derivatives
CN101365715B (zh) 2005-10-07 2013-03-27 P·安杰莱蒂分子生物学研究所 基质金属蛋白酶11疫苗
JP5960944B2 (ja) * 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
KR101629504B1 (ko) * 2014-04-14 2016-06-10 주식회사 엘지생활건강 사이토카인 조합을 함유하는 피부 상태 개선용 조성물
JP2020517615A (ja) * 2017-04-21 2020-06-18 プレシゲン，インコーポレイテッド 硬皮症の処置のための、マトリックス金属タンパク質分解酵素を含む自己由来細胞の送達

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279840A (ja) * 1988-04-28 1989-11-10 Wakunaga Pharmaceut Co Ltd 新規外用組成物
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
PE20011095A1 (es) 2001-10-27
WO2001049309A2 (en) 2001-07-12
AR027122A1 (es) 2003-03-12
GB9930768D0 (en) 2000-02-16
AU1878201A (en) 2001-07-16
GT200000224A (es) 2002-06-15
EP1242120A2 (en) 2002-09-25
CA2395487A1 (en) 2001-07-12
JP2003519193A (ja) 2003-06-17
CO5271671A1 (es) 2003-04-30
UY26514A1 (es) 2001-07-31
WO2001049309A3 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
BR0014384A (pt) Compostos para o tratamento da isquémia
ES2176600T3 (es) Derivado de la propiofenona y procedimientos para su preparacion.
BR0200782A (pt) Compostos para o tratamento da isquemia
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
AR020055A1 (es) Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma.
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
ES2159591T3 (es) Composicion de liberacion controlada.
BR0009830A (pt) Composições para cuidados com a pele contendo uma combinação de substâncias ativas para cuidados com a pele
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DE69507185D1 (de) Arzneimittel zur Behandlung von Osteoporose
AR007582A1 (es) Composicion para el lavado de la piel, procedimiento para prepararla y el uso de la misma para la fabricacion de medicamentos dado el caso, para eltratamiento cosmetico de la piel.
ATE333896T1 (de) Vaskularisierungsinhibitoren
NO20004282D0 (no) Matriksproteinpreparater for sÕrheling
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ECSP003859A (es) Composicion para el tratamiento de tejidos dañados
MD2550C2 (ro) Preparat antibiotic cu eliberare lenta a ingredientului activ şi utilizare a acestuia
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
CO5271686A1 (es) Nuevo uso de (r)-(-)-2-[5-(4-flurofenil)-3-piridilmetil- aminometil]-cromano y de sus sales aceptables para uso fisiologico
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.